.Pharmacolibrary.Drugs.ATC.L.L01FD02

Information

Pertuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2). It is primarily used in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic breast cancer. Pertuzumab is approved for clinical use and is part of the standard of care in HER2-positive breast cancer.

Pharmacokinetics

Pharmacokinetic parameters from population pharmacokinetic analysis, adult cancer patients (mainly breast cancer), mostly female, typical clinical dosing.

References

1. Tan, AR, et al., & Jackisch, C (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology 22(1) 85–97. DOI:10.1016/S1470-2045(20)30536-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33357420

2. Luo, Y, et al., & Xu, B (2019). Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. Anti-cancer drugs 30(8) 866–872. DOI:10.1097/CAD.0000000000000808 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31305270

3. Liu, SN, et al., & Kirschbrown, WP (2021). Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics. Journal of clinical pharmacology 61(8) 1096–1105. DOI:10.1002/jcph.1855 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33719071

Revisions

• 06/2025 initial generated model